Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Ertapenem
2. Ertapenem Sodium
3. Invanoz
1. Ertapenem Sodium
2. Ertapenem Monosodium
3. Ertapenem Sodium [usan]
4. Ertapenem Monosodium (90per Cent)
5. 153773-82-1
6. Mk 0826
7. Sodium;(4r,5s,6s)-3-[(3s,5s)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
8. 2t90ke67l0
9. Mk 826
10. Unii-2t90ke67l0
11. L 749345
12. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 3-(((3s,5s)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, Monosodium Salt, (4r,5s,6s)-
13. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, Monosodium Salt, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))-
14. Sodium (4r,5s,6s)-3-({(3s,5s)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
15. Sodium (4r,5s,6s)-3-({(3s,5s)-5-[(m-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
16. Sodium (4r,5s,6s)-3-({(3s,5s)-5-[(m-carboxyphenyl)carbamoyl]-3-pyrrolidinyl}thio)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
| Molecular Weight | 497.5 g/mol |
|---|---|
| Molecular Formula | C22H24N3NaO7S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 497.12326557 g/mol |
| Monoisotopic Mass | 497.12326557 g/mol |
| Topological Polar Surface Area | 192 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 882 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
* Treatment:
Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:
- intra-abdominal infections;
- community-acquired pneumonia;
- acute gynaecological infections;
- diabetic foot infections of the skin and soft tissue.
* Prevention:
Invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01DH03
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28391
Submission : 2014-06-16
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2022-09-30
Pay. Date : 2022-08-19
DMF Number : 37232
Submission : 2022-08-29
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2025-06-18
Pay. Date : 2025-05-30
DMF Number : 37463
Submission : 2023-03-02
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2018-04-20
Pay. Date : 2018-01-11
DMF Number : 32424
Submission : 2018-01-12
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2017-03-03
Pay. Date : 2016-08-22
DMF Number : 30709
Submission : 2016-05-19
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30123
Submission : 2016-01-07
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Apotex Corp
Ertapenem Sodium
Drug Cost (USD) : 18,550,431
Year : 2023
Prescribers : 14601
Prescriptions : 36676

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Auromedics-Eugi
Ertapenem Sodium
Drug Cost (USD) : 9,541,109
Year : 2023
Prescribers : 11517
Prescriptions : 25200

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Auromedics-Nova
Ertapenem Sodium
Drug Cost (USD) : 351,827
Year : 2023
Prescribers : 642
Prescriptions : 1526

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bluepoint Labor
Ertapenem Sodium
Drug Cost (USD) : 1,373,045
Year : 2023
Prescribers : 1652
Prescriptions : 2743

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Dr.Reddy'S Lab
Ertapenem Sodium
Drug Cost (USD) : 6,134,274
Year : 2023
Prescribers : 6480
Prescriptions : 13454

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Fosun Pharma Us
Ertapenem Sodium
Drug Cost (USD) : 2,541,579
Year : 2023
Prescribers : 3453
Prescriptions : 6964

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Fresenius Kabi
Ertapenem Sodium
Drug Cost (USD) : 18,599,397
Year : 2023
Prescribers : 9963
Prescriptions : 25903

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Hospira/Pfizer
Ertapenem Sodium
Drug Cost (USD) : 507,798
Year : 2023
Prescribers : 345
Prescriptions : 884

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Northstar Rx Ll
Ertapenem Sodium
Drug Cost (USD) : 1,447,221
Year : 2023
Prescribers : 1208
Prescriptions : 2290

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Par Pharm.
Ertapenem Sodium
Drug Cost (USD) : 10,014,808
Year : 2023
Prescribers : 6580
Prescriptions : 16442

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Ertapenem API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ertapenem manufacturer or Ertapenem supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ertapenem manufacturer or Ertapenem supplier.
PharmaCompass also assists you with knowing the Ertapenem API Price utilized in the formulation of products. Ertapenem API Price is not always fixed or binding as the Ertapenem Price is obtained through a variety of data sources. The Ertapenem Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Invanz manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Invanz, including repackagers and relabelers. The FDA regulates Invanz manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Invanz API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Invanz manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Invanz supplier is an individual or a company that provides Invanz active pharmaceutical ingredient (API) or Invanz finished formulations upon request. The Invanz suppliers may include Invanz API manufacturers, exporters, distributors and traders.
click here to find a list of Invanz suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Invanz DMF (Drug Master File) is a document detailing the whole manufacturing process of Invanz active pharmaceutical ingredient (API) in detail. Different forms of Invanz DMFs exist exist since differing nations have different regulations, such as Invanz USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Invanz DMF submitted to regulatory agencies in the US is known as a USDMF. Invanz USDMF includes data on Invanz's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Invanz USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Invanz suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Invanz Drug Master File in Korea (Invanz KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Invanz. The MFDS reviews the Invanz KDMF as part of the drug registration process and uses the information provided in the Invanz KDMF to evaluate the safety and efficacy of the drug.
After submitting a Invanz KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Invanz API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Invanz suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Invanz as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Invanz API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Invanz as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Invanz and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Invanz NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Invanz suppliers with NDC on PharmaCompass.
Invanz Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Invanz GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Invanz GMP manufacturer or Invanz GMP API supplier for your needs.
A Invanz CoA (Certificate of Analysis) is a formal document that attests to Invanz's compliance with Invanz specifications and serves as a tool for batch-level quality control.
Invanz CoA mostly includes findings from lab analyses of a specific batch. For each Invanz CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Invanz may be tested according to a variety of international standards, such as European Pharmacopoeia (Invanz EP), Invanz JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Invanz USP).